A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

Clinical trial NCT07048197 · RECRUITING

Trial details

NCT number: NCT07048197
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)

Start date: 2025-06-20
Primary completion: 2028-11-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.